COA566
Malaria
NovartisPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malaria cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Artesunate University of Khartoum | Phase 4 | BBB |
Hydroxyurea Indiana University | Phase 3 | BB |
Quinine University of Khartoum | Phase 4 | BB |
ama1-c1 National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1/2 | B |
sar97276a Sanofi | Phase 2 | CCC |
View all 13 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →